Latest Cell signaling Stories
Cancer research has truly gone to the dogs as scientists at the University of Illinois have announced the start of phase I trials for a drug showed good results in the treatment of spontaneously occurring cancers in pet dogs.
We the People and our synaptic serotonin systems are the focus found in four 2015 (short) science tales from the National Institutes of Health (PubMed). In today’s update, author Bryan W.
International Collaboration's initial focus is to solve 3D structures of significant drug targets for diabetes, cancer and mental disorders LOS ANGELES and SHANGHAI, Feb.
- Company to focus pipeline development on severe inflammation and fibrosis - GOTHENBURG, Sweden, Jan.
LONDON and BOSTON, January 23, 2015 /PRNewswire/ -- Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted
The January 26, 2015 Webinar will focus on the form of cellular signaling mediated by extracellular membrane vesicles in the application of stem cells as therapeutics Yorba
LONDON and BOSTON, January 22, 2015 /PRNewswire/ -- Stable Receptor, X-ray Structure and Hit Series Generated for PAR2, a Previously
Brett Smith for redOrbit.com - Your Universe Online Medical researchers have known that essential oils found in plants can inhibit the growth of certain cancer cells, and a new study from German researchers has uncovered new details on the exact mechanism behind this protection. Published in the journal Archives of Biochemistry and Biophysics, the new study looked at a number of terpenes, the active ingredients in essential oils with respect to cancer research. Terpenes can set off...
Findings supporting novel approaches to inhibit or enhance immune responses for treating autoimmunity and cancer published in Nature Chemical Biology. ANN ARBOR, Mich., Jan.
Follows Positive Phase 2 Data Showing Rapid, Robust and Sustained Antidepressant Effect of Adjunctive GLYX-13 in Patients with Major Depressive Disorder EVANSTON, Ill., Dec.
- A political dynamiter.